about
The tumor targeted superantigen ABR-217620 selectively engages TRBV7-9 and exploits TCR-pMHC affinity mimicry in mediating T cell cytotoxicity.Recent advances in the application of antibodies as therapeutics.Bispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: preparing for the future.Naptumomab estafenatox: targeted immunotherapy with a novel immunotoxin
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Naptumomab estafenatox: a new immunoconjugate.
@en
Naptumomab estafenatox: a new immunoconjugate.
@nl
type
label
Naptumomab estafenatox: a new immunoconjugate.
@en
Naptumomab estafenatox: a new immunoconjugate.
@nl
prefLabel
Naptumomab estafenatox: a new immunoconjugate.
@en
Naptumomab estafenatox: a new immunoconjugate.
@nl
P2093
P2860
P1476
Naptumomab estafenatox: a new immunoconjugate.
@en
P2093
Hossein Borghaei
Matthew K Robinson
R Katherine Alpaugh
P2860
P304
P356
10.1517/14712590903575620
P407
P577
2010-02-01T00:00:00Z